Total plasma fibronectin as a marker of pregnancy-induced hypertensive disorders: A longitudinal study*1

Paarlberg, K.M.; Jong, C.L.D. de; Geijn, H.P. van; Kamp, Gerard J. van; Heinen, A.G.J.J.; Dekker, Gustaaf A.

doi:10.1016/s0029-7844(97)00683-2

Cited by 35 publications

(28 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In rats, short term alcohol leads to accumulation of fibronectin in the heart (Vendemiale et al, 2001). In pregnant women, increased plasma fibronectin levels is utilized as a marker for gestational hypertensive disorders (Paarlberg et al, 1998) and fetal fibronectin is associated with the onset of labor (Cunze et al, 1996). Finally, these data may also have physiologic implications on uterine endothelial cell shape and function (Grinnell et al, 1982).…”

Section: Discussionmentioning

confidence: 99%

High-throughput caveolar proteomic signature profile for maternal binge alcohol consumption

Ramadoss

Liao

Chen

et al. 2010

Alcohol

View full text Add to dashboard Cite

Currently, no single marker is sensitive and specific enough to be considered a reliable biomarker for prenatal alcohol exposure. To identify a proteomic signature profile for maternal alcohol consumption, we performed high throughput proteomics on maternal endothelial caveolae exposed to moderate binge-like alcohol conditions. In these specialized lipid ordered microdomains which contain a rich assembly of proteins, we demonstrate that moderate binge-like alcohol resulted in a distinctive maternal caveolar proteomic signature with important proteins being dramatically decreased/knocked out in the alcoholic profile. These proteins span from histones and basic structural proteins like tubulin α to proteins involved in trafficking, deubiquitination, cell signaling, and cell-cell adhesion. The profile also suggests an important role for the mother and the utero-placental compartment in the pathogenesis of Fetal Alcohol Spectrum Disorders (FASD). These data demonstrate that the caveolar proteomic signature created by alcohol shows a promising direction for early detection of FASD.

show abstract

Section: Discussionmentioning

confidence: 99%

High-throughput caveolar proteomic signature profile for maternal binge alcohol consumption

Ramadoss

Liao

Chen

et al. 2010

Alcohol

View full text Add to dashboard Cite

show abstract

“…22,23 Such a test would enable identification of a high-risk group that may benefit from close monitoring, steroid administration, and anti-hypertensive therapy. VEGF antagonists such as sflt-1 may counteract the endothelial effects of VEGF and thus prevent or ameliorate the disease and allow progression of the pregnancy.…”

Section: Hunter Et Al Serum Vegf In Preeclampsia 967mentioning

confidence: 99%

Serum Levels of Vascular Endothelial Growth Factor in Preeclamptic and Normotensive Pregnancy

Hunter¹,

Aitkenhead²,

Caldwell³

et al. 2000

Hypertension

105

View full text Add to dashboard Cite

Abstract-The purpose of these studies was first to determine if vascular endothelial growth factor (VEGF), a vascular permeability agent, is increased in the serum of women with preclinical and clinical preclampsia (PE), and second to determine how these levels change after delivery. Twenty preeclamptic and 25 normotensive women at term consented to have blood taken pre-and post-delivery. Ten preeclamptic, 10 gestational hypertensive, and 28 normotensive women had blood collected respectively at 12, 20, and 30 weeks gestation and predelivery. Serum was extracted from all samples, and VEGF concentrations were determined by radioimmunoassay. Predelivery, the median serum VEGF concentration in the preeclamptic group was 51.7 ng/mL, and in the control group the concentration was 13.9 ng/mL (PϽ0.0001). Serum VEGF concentrations fell within 24 hours of delivery in both groups, which resulted in median values of 3.8 ng/mL and 3.2 ng/mL respectively (PϽ0.3). At 12 and 20 weeks, there was no significant difference between the serum VEGF concentrations in the 3 groups (PϽ0.3, 0.052 respectively). At 30 weeks, prior to the onset of clinical PE, the serum VEGF levels in the eventual preeclamptic group were elevated significantly compared with the gestational hypertensive and normotensive groups (PϽ0.001). Predelivery serum VEGF concentrations were significantly elevated in the preeclamptic group and were similar to those in the first study (PϽ0.0001). These findings suggest that VEGF may be important in the pathophysiology of PE and has the potential to act as a preclinical marker for the condition.

show abstract

“…One study measured fibronectin at 13 weeks, but the authors only performed a trend analysis based on 3 consecutive measurements in the first, second and third trimester [16] . Our data indicate that former PS patients -previously identified with a subnormal pre-pregnant PV -may already have raised fibronectin levels at 12 weeks.…”

Section: Discussionmentioning

confidence: 99%

Circulating Fibronectin and Plasminogen Activator Inhibitor-2 Levels as Possible Predictors of Recurrent Placental Syndrome: An Exploratory Study

Al‐Nasiry¹,

Ghossein‐Doha²,

Marzano³

et al. 2016

Gynecol Obstet Invest

View full text Add to dashboard Cite

Background/Aim: Placental syndromes (PS) are characterized by endothelial dysfunction complicating placental dysfunction. Possible markers for endothelial dysfunction and amount of trophoblast are fibronectin and plasminogen activator inhibitor-2 (PAI-2), respectively. We aimed (1) to determine whether in women with recurrent PS (rPS), this complication is preceded by deviating fibronectin- and PAI-2-levels, and (2) whether this is dependent on pre-pregnant plasma volume (PV). Methods: In 36 former patients, we determined fibronectin- and PAI-2-levels in blood-samples collected preconceptionally and at 12-16 weeks in their next pregnancy. Differences were analyzed between pregnancies with rPS (n = 12) and without rPS (non-rPS, n = 24) using linear mixed models, with subanalyses based on pre-pregnant normal or subnormal PV. Results: We observed higher fibronectin-levels at 12-16 weeks (p < 0.05 and p < 0.01, respectively) and lower PAI-2-levels at 16 weeks (p < 0.01) in the rPS subgroup, the intergroup differences being larger in women with subnormal PV. Conclusion: We showed that former PS patients who developed rPS have raised fibronectin- and reduced PAI-2-levels already in early/mid pregnancy. These deviations are even more prominent in women with subnormal pre-pregnant PV, supporting development of a 2-step screening program for former patients to identify the high-risk subgroup of women who may benefit from closer surveillance.

show abstract

Total plasma fibronectin as a marker of pregnancy-induced hypertensive disorders: A longitudinal study*1

Cited by 35 publications

References 19 publications

High-throughput caveolar proteomic signature profile for maternal binge alcohol consumption

High-throughput caveolar proteomic signature profile for maternal binge alcohol consumption

Serum Levels of Vascular Endothelial Growth Factor in Preeclamptic and Normotensive Pregnancy

Circulating Fibronectin and Plasminogen Activator Inhibitor-2 Levels as Possible Predictors of Recurrent Placental Syndrome: An Exploratory Study

Contact Info

Product

Resources

About